Celltrion Celebrates Brazilian Tender Win For Infliximab
Remsima Win Follows Truxima (Rituximab) And Herzuma (Trastuzumab) Biosimilars
Executive Summary
Celltrion’s Remsima infliximab biosimilar has won a Brazilian federal tender as well as several individual state bids, following earlier awards for the Korean firm’s Truxima (rituximab) and Herzuma (trastuzumab) biosimilars.
You may also be interested in...
Eurofarma Biosimilars Deal Broadens Access To Latin America For Henlius
Shanghai Henlius Biotech has announced a licensing deal for three biosimilars – bevacizumab, rituximab and trastuzumab – with Brazil’s Eurofarma. The agreement, which could be worth as much as $50.5m, gives the Chinese company enhanced access to Latin America as it continues to broaden its global footprint.
Celltrion Sees ‘Record-High Revenue’ With Increasing Infliximab Sales
South Korea’s Celltrion has delivered a strong fourth quarter in FY21 based on the increase in infliximab sales across all markets as well as a contribution from its Regkirona COVID-19 treatment. The company expects modest top-line growth to continue by launching at least one biological product every year.
Celltrion Wins Brazilian Trastuzumab and Rituximab Tender
Celltrion has won a Brazilian tender to supply two oncology biosimilars – Herzuma (trastuzumab) and Truxima (rituximab) – to the Brazilian market. Based on its successful bid in Brazil, the company plans on expanding its direct sales business model to Peru and Chile in the third quarter of this year.